PMV Pharmaceuticals Inc
Research PMV Pharmaceuticals Inc (PMVP) on Bullrun: market cap USD 69.77M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPMVP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 69.77M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 78.34M
- Free cash flow-USD 75.02M
Valuation Snapshot
latest market cap is USD 69.77M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 77.74M | -USD 73.61M | n/a | -1.48 | USD 37.98M | USD 838.00K | USD 104.71M |
| FY2024 | USD 0 | -USD 58.90M | -USD 51.94M | n/a | -1.14 | USD 40.88M | USD 1.19M | USD 176.08M |
| FY2023 | n/a | -USD 68.96M | -USD 56.62M | n/a | -1.44 | USD 37.71M | USD 13.29M | USD 225.69M |
| FY2022 | n/a | -USD 73.32M | -USD 71.74M | n/a | -1.61 | USD 108.30M | USD 12.59M | USD 246.03M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 69.77M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 66.66M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 78.42M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 158.59M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 397.29M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.05B | n/a | n/a | n/a |
About PMV Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PMV Pharmaceuticals Inc's market cap?
PMV Pharmaceuticals Inc's market capitalization is USD 69.77M.
What does PMV Pharmaceuticals Inc do?
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.